Combination Therapies and New Molecular Targets—Presentations from AACR 2021

David Spigel, MD

Combination Therapies and New Molecular Targets—Presentations from AACR 2021

AACR & ASCO 2021 – Midyear Review

Chief Scientific Officer; Director
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN

Dr David Spigel reviews potentially practice-changing data on EGFR-TKI combination therapies in NSCLC, new approaches to advanced NSCLC and CNS involvement, and hopeful early data with novel targeted agents.

Combination Therapies and New Molecular Targets—Presentations from AACR 2021

Related Items